Are Medicare plans complying with CMS regulations?

Expert Review of Pharmacoeconomics and Outcomes Research

Volumn 8, Issue 2, 2008, Pages 133-139

  Cohen, Joshua ^a   Young, Brian ^a   Rochon, Stephanie ^a   Faden, Laura ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CMS regulations; Cost sharing; Formulary management; Medicare prescription drug benefit

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTINEOPLASTIC AGENT; IMMUNOSUPPRESSIVE AGENT; NEUROLEPTIC AGENT;

ARTICLE; DRUG COST; DRUG FORMULARY; DRUG LEGISLATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SERVICE; MEDICAID; MEDICARE; PRACTICE GUIDELINE; PRESCRIPTION; REIMBURSEMENT;

EID: 46949086203     PISSN: 14737167     EISSN: 17448379     Source Type: Journal    
DOI: 10.1586/14737167.8.2.133     Document Type: Article

References (11)

1. Ganther-Urmie J, Nair K, Valuck R, McCollum M, Lewis S, Turpin R. Consumer attitudes and factors related to prescription switching decisions in multitier co-payment drug benefit plans. Am. J. Manag. Care 10, 201-208 (2004).
2. Huskamp H, Keating N. The new Medicare drug benefit formularies and their potential effects on access to medications. J. Gen. Int. Med. 20, 662-665 (2005).
3. Formulary "negative" change requests unexpectedly increase in early 2007. The Pink Sheet Daily, May 11 (2007).
4. Institute of Medicine, Committee on Quality of Health Care. In: Crossing the Quality Chasm: a New Health System for the 21st Century. National Academies Press, DC, USA (2001).
5. McClellan M. Drug safety reform at the FDA - pendulum swing or systematic improvement? N. Engl. J. Med. 356, 1700-1702 (2007).
6. United States Pharmacopeia USP-DI. Volume I: Drug Information for the Health Care Professional (23rd Edition). Thomson, CO, USA (2006).
7. Martindale: the Extra Pharmacopeia (31st Edition). Reynolds J (Ed.). Royal Pharmaceutical Society, London, UK (1996).
8. Bowman J, Rousseau A, Silk D, Harrison C. Access to cancer drugs in Medicare Part D: formulary placement and beneficiary cost sharing in 2006. Health Affairs 25(5), 1240-1248 (2006).
9. Hamel M, Epstein A. Prior-authorization programs for controlling drug spending. N. Engl. J. Med. 351, 2156-2158 (2004).
10. Representative Pete Stark considering making Medicare's protected drug classes permanent. The Pink Sheet Daily 69(27), july 2 (2007).
11. Wertheimer A, Levy R, O'Connor T. Too many drugs? The clinical and economic value of incremental innovations. In: Investing in Health: the Social and Economic Bnefits of Health Care Innovation. Farquhar I, Summers K, Sorkin A (Eds). Elsevier, Amsterdam, The Netherlands, 77-118 (2001).